TY - JOUR
T1 - Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer
AU - Ma, Rong
AU - Xu, Heng
AU - Wu, Jianzhong
AU - Sharma, Ashok Kumar
AU - Bai, Shan
AU - Dun, Boying
AU - Jing, Changwen
AU - Cao, Haixia
AU - Wang, Zhuo
AU - She, Jin-Xiong
AU - Feng, Jifeng
N1 - Funding Information:
This research is supported by the National Science Foundation of China (grant number 81272244 and 81372396) and general program from Jiangsu province health department (grant number H201410).
PY - 2017
Y1 - 2017
N2 - Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25% of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.
AB - Lung cancer is one of the most prevalent cancers and has very poor treatment outcome. Biomarkers useful for screening and assessing early therapeutic response may significantly improve the therapeutic outcome but are still lacking. In this study, serum samples from 218 non-small cell lung cancer (NSCLC) patients, 34 small cell lung cancer (SCLC) patients and 171 matched healthy controls from China were analyzed for 11 proteins using the Luminex multiplex assay. Eight of the 11 proteins (OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF) are significantly elevated in NSCLC and SCLC (p = 10-5-10-59). At the individual protein level, OPN has the best diagnostic value for NSCLC (AUC = 0.92), two acute phase proteins (SAA and CRP) have AUC near 0.83, while CEA and CYFRA21.1 also possess good AUC (0.81 and 0.77, respectively). More importantly, several three-protein combinations that contain OPN and CEA plus one of four proteins (CRP, SAA, CYFRA21.1 or NSE) have excellent diagnostic potential for NSCLC (AUC = 0.96). Four proteins (CYFRA21.1, CRP, SAA and NSE) are severely reduced and three proteins (OPN, MIF and NSE) are moderately decreased after platinum-based chemotherapy. Therapeutic response index (TRI) computed with 3-5 proteins suggests that approximately 25% of the NSCLC patients respond well to the therapy and TRI is significantly correlated with pre-treatment protein levels. Our data suggest that therapeutic response in NSCLC patients can be effectively measured but personalized biomarkers may be needed to monitor different subsets of patients.
KW - Biomarkers
KW - Inflammation
KW - NSCLC
KW - Therapeutic response
KW - Tumor antigens
UR - http://www.scopus.com/inward/record.url?scp=85015783536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015783536&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.14782
DO - 10.18632/oncotarget.14782
M3 - Article
C2 - 28121629
AN - SCOPUS:85015783536
SN - 1949-2553
VL - 8
SP - 18901
EP - 18913
JO - Oncotarget
JF - Oncotarget
IS - 12
ER -